AI assistant
ARIX BIOSCIENCE PLC — Regulatory Filings 2018
Apr 5, 2018
4968_rns_2018-04-05_ad505cf0-ba11-475d-84a4-d24f58559baf.html
Regulatory Filings
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 8704J
Arix Bioscience Plc
05 April 2018
Arix Bioscience to present at H.C. Wainwright & Co. Global Life Sciences Conference on 10 April 2018
LONDON, 5 April 2018: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience") a global healthcare and life science company supporting medical innovation, announces that Joe Anderson, CEO, will present at the H.C. Wainwright & Co. Global Life Sciences Conference on 10 April 2018, at 11.30 CEST at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
A webcast of the presentation will be accessible live and available to replay on Arix's website at https://arixbioscience.com/presentations.
Ends
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Investor Relations Manager
+44 (0)20 7290 1072
Consilium Strategic Communications
Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan
+44 (0)20 3709 5700
About Arix Bioscience plc
Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.
Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASSLFMLFASELL